Inclusion Criteria:

          -  Must have evidence of c-MET dysregulation from either local data or the results of
             molecular pre-screening evaluations.

          -  Confirmed diagnosis of a solid tumor.

          -  Measureable lesion.

          -  Refractory to currently available treatment or no therapies available.

          -  18 years or older.

          -  ECOG performance status of 0, 1, or 2.

          -  Obtained written informed consent.

        Additional inclusion criteria for NSCLC patients EGFRwt with high c-MET expression:

          -  Written documentation of EGFRwt NSCLC.

          -  Written documentation of c-MET positivity.

          -  Patients should not have received more than three prior lines of antineoplastic
             therapy for NSCLC.

          -  Presence of at least one measurable lesion as determined by modified RECIST version
             1.1

        Exclusion Criteria:

        HCC with liver dysfunction greater than Child-Pugh A. Previous treatment with a c-MET
        inhibitor or HGF-targeting therapy. Symptomatic CNS metastases that are neurologically
        unstable or requiring increasing doses of steroids to control their CNS disease.

        Any CNS deficits. For patients with GBM, CNS symptoms grade 2 or greater. Subjects with
        significant or uncontrolled cardiovascular disease (eg, uncontrolled hypertension,
        peripheral vascular disease, congestive heart failure, cardiac arrhythmia, or acute
        coronary syndrome) within 6 months of starting study treatment or heart attack within 12
        months of starting study treatment.

        Receiving anti-epileptic drugs that are known to be strong inducers of CYP3A4. Prior or
        current anti-angiogenic therapy for patients with GBM. Radiation therapy within ≤ 4 weeks
        (< 12 for GBM) prior to the first dose of study drug or limited field radiotherapy within ≤
        2 weeks (< 12 weeks GBM) prior to the start of study treatment. Any persistent side effect
        of prior radiotherapy must be resolved to ≤ Grade 1 prior to the first dose of study drug.

        Additional exclusion criteria for NSCLC patients EGFRwt with high c-MET expression:

          -  Patients who have received more than three prior lines of antineoplastic therapies

          -  Any unresolved toxicity (CTCAE grade > 1) from previous anti-cancer therapy or
             radiotherapy, except alopecia

          -  Patients have received anti-cancer therapies within the following time frames prior to
             the first dose of study treatment:

               -  Conventional cytotoxic chemotherapy: ≤4 weeks (≤6 weeks for nitrosoureas and
                  mitomycin-C)

               -  Biologic therapy (e.g., antibodies): ≤4 weeks

               -  Non-cytotoxic small molecule therapeutics: ≤5 half-lives or ≤2 weeks (whichever
                  is longer)

               -  Other investigational agents: ≤4 weeks

               -  Radiation therapy (palliative setting is allowed.): ≤4 weeks

               -  Major surgery: ≤2 weeks

        Other protocol-defined inclusion/exclusion criteria may apply.